Subcategories
-
مقالات
- Article Count:
- 87
Researchers of Vienna University could succeed in making the first laboratory heart. As reported by Scientific, the researchers of Vienna University could make a compound, which changes fetal and adult fundamental cells to heart ones.
Primary stage of the said project has successfully been accomplished and at this stage, generated heart cells have had heartbeats inside laboratory dishes.
This heart is made using DNA of the patient himself. There is a weak possibility to repair heart tissue by itself. However, using this chemical compound, this repair process will be accomplished. Presently, there are many patients all over the world, waiting for heart grafting.
As reported by Mehr News Agency, the achievement of the biologists of California University in San Diego in using seaweed for generating a medicine for treatment of cancer, has been published in the Journal of “Articles of National Academy of Sciences” and has opened doors for generating this protein and other proteins in more and cheaper quantities.
Stephan Mifield, Professor of Biology of California University in San Diego and Head of Center of San Diego Seaweed Biotechnology Center, as a research Institute, working on generating of biological fuel from seaweed, stated: “Since we generate the said medicine using the said seaweed, it is possible to decease its protraction cost accordingly”.
This method may be used for more advanced and modern plans of medicine so that the said medicines will be used for treatment of cancer and other forms of human diseases in new forms.
He further added: “The said medicines can’t be generated from bacterium because bacteria lack bending proteins: in three-dimensional complicated forms. Moreover, said proteins can’t be generated from cells of mammals because poison will damage the same.
This achievement has been obtained pursuant to seven years of working at laboratory in order to find that “Chlamydomonas Reinhardt” is a kind of green seaweed, which is mainly used in biological laboratories is a genetic model of organism, which may generate a wide range of medical proteins used for humans, at remarkable quantities and even at low cost compared to bacteria and cells of mammals.
Mayfield et al have achieved the first progress five years ago. At that time, they could generate Amyloid protein serum from seaweed. One year later, said researchers could obtain a human antibody protein from seaweed and in 2010, they showed that a more complicated protein, which is used as a human medicine for treatment of patients, suffering from pulmonary Emphysema, may be obtained from seaweed accordingly.
As their latest achievement, the said scientist could generate a three dimensional and complicated protein with domain benefiting from seaweed genetic engineering. One of the said domains contains one antibody, which is joined to carcinoma cells and another domain contains a poison, which limits cancer cells.
Presently, this protein fusion, which has been done from seaweed by scientists at laboratory is a complicated process, which is being generated by pharmaceutical companies, spending over 100,000.- Dollars for this purpose. However, since the said protein has been generated from seaweed in laboratory, it may be possible to decrease respective costs accordingly.
The researchers of medical sciences are of this opinion that Mediterranean diet, full of vegetables, fruits, fish and olive oil, prevents cerebral stroke.
As reported by the reporter of borderless physicians’ website, researchers of Navarra University Clinic in Spain emphasize that fruits, vegetables, dried fruits, and olive oil and an average level of fish and chicken prevent cerebral stroke.
Dr. Ramon Storch from Internal Medicine Ward of the Clinic of a hospital in Barcelona of Spain and Dr. Martinez Gonzales, Preventive Medicine Department of Public Health of Navarra University Clinic stated: “Danger of cerebral stroke has been decreased among the individuals, who benefited from Mediterranean diet”.
Spanish researchers have commented that they contracted the said researches on 7447 candidates, who were allowed to consume high quantity of calorie without exercising.
Candidates in the said research have determined one of three diets at random.
Mediterranean diet contained dried fruits, olive oil, fish, chicken, low dairies, red meat or processed meat or pastries, olive oil supplements, and the Mediterranean diet contained dried fruits, low fat food, including bread, potato and macaroni.
Researchers studied the candidates at the age of 55-88 for the entire five years. All individuals were at high risk of cardiac disorders. However, none of them has had cardiovascular problems upon commencement of the said research.
These researches, which were published in New England Medical Journal, compared the individuals who were benefiting from low fat diet and those who were benefiting from Mediterranean diet, enriched with olive oil.
The results of the said researches have revealed that cerebral stroke has been decreased by 46% among the individuals, who benefited from Mediterranean diet.
In Mediterranean diet, there are a huge quantity of vegetable foods such as fruits, vegetables, breads and other materials, made of grains, potato, cereals, and other grains; foods are made of materials, which are fresh and seasonal, grown in the said region and the least process is done during cooking process on the said foods accordingly.
Fresh fruits in the said diet are consumed as daily desserts. Pastries, containing concentrated sugar or honey are consumed several times every week.
Olive oil is a main source, providing fat of the said diet. Dairy protract, especially cheese and yogurt are consumed every day at low or medium level. Fish and chicken are used at low or medium level. One to four eggs are consumed every week. Red meat is consumed low.
Food and Drug Administration of America has confirmed generating the first vaccine for cancer, which entered into a new era of treatment of cancers all over the world.
This vaccine, under the name of “Provenge” has been generated, aiming at treatment of prostate cancer. The said vaccine has been used during clinical test periods and, compared to placebos, the said vaccine could increase lifetime of patients for four months. This medicine is not regarded as a procedure for treatment or prevention of the respective disease and it is not similar to the vaccines, which have been generated for treatment of measles or Hepatitis. But, it is regarded as a treatment vaccine. It means that the said vaccine may improve immunity system of patients. Ten samples of vaccines have been generated for treatment of cancer so far. However, “Provenge” vaccine is the first sample, which has been confirmed by FDA. Non-confirmation of the said medicine had led to severe objection of patients and investors for about three years. The said vaccine is manufactured for each patient according to an order placed for this purpose. It means that while blood globules of a patient are collected and specific immunity cells are extracted from the said cells accordingly. Then, final cells are injected to the patient for three times within a one-month period. The said vaccines costs 93,000.- Dollars. Common treatment procedures of cancer namely radiotherapy, chemotherapy and even prostatectomy shall cause many damages to patients. Thus, a medicine, which is able to stimulate and to improve natural body immunity system of patients may be regarded a valuable replacement for the said procedures. Extent of side-effects of the said vaccine is too limited including fever, fatigue and pain. According to the report of Pop Science, Provenge Vaccine is used for the patients, who suffering from prostate cancer, with metastasis to their entire body. In 2009, National Cancer Institute of America reported about 192000 new cases of Prostate Cancer. About 27000 patients out of the said cases died due to the said disease.
Relying on unsparing efforts and endeavors of the researchers of Infectious and Tropical Diseases Research Center of Esfahan University of Medical Sciences, a new species of mycobacterium has been discovered, registered to Iran at global scientific banks under the name of “Mycobacterium Iranicum”.
As reported by ISNA, “Mycobacterium”, which was discovered by Dr Hassan Shojaee, Professor of Esfahan University of Medical Sciences and his research team, causes Semi-tuberculosis Meningitis as well skin lesions in human body.
As stated by Dr. Shojaee, the said bacterium has simultaneously been discovered at six research centers in Greek, the Netherlands, Sweden, USA, Italy and Iran. Since Iran has introduced the said bacterium to International Committee for Registration of Microbes sooner, new Mycobacterium has been registered to the discovering country i.e. Iran under the name of Mycobacterium Iranicum.
An English Company is going through the process of obtaining a license to use a new vaccine, which prevents development of Meningitis- Type B. This Company has claimed that the said vaccine will be presented to the word in near future.
As reported by reporter for the site of Borderless Physicians, Meningitis is an inflammation of myelin and cerebral membrane, affecting most of the adolescences with a mortality of 14-15%. Many patients, who have recovered, are affected by permanent neural injuries or have lost their hearing forever.
Certain vaccines have been produced in order to campaign against Meningitis of types A and C. However, none of the said vaccines has been effective for Meningitis of Type B. Meningitis of Type A is the most prevalent type of the said disease in Africa.
Meningitis of Type B is the most common type of the said complication in Europe. This fatal disease kills one out of ten patients, who suffer from the said complication. Even if the said disease is treated, 1/5th of those patients who had this kind of disease suffer from neural or hearing complications forever.
On average, 1870 cases of Meningitis of Type B are reported ever year in England. 200 cases out of total reported ones die due to the said disease. Half of those who die because of this type of Meningitis are kids, who are below five years.
Furthermore, over 400 kids, suffering from the said disease are affected by severe complications namely impairment, blindness, deafness, and cerebral injuries.
Although it has been reported that vaccination plans for campaign against other types of Meningitis were successful in England, presently, there is no vaccine against Meningitis of Type B in the nation.
Meningo Cocci B or Meningitis of Type B is the most prevalent type of bacterium meningitis in England. This type of Meningitis is regarded as the most fatal diseases as well.
Since there are many varieties of Meningitis of Type B, producing respective vaccine, which could prevent development of the said disease is a difficult task.
Bexsero is the first vaccine, which prevents development of the fatal type of Meningo Cocci B, which in some cases leads to death only within a few hours.
European Medical Institute which supervises over a supervising organization of medicines in England has stated its auspicious decision to use the aforesaid vaccine. Thus, it so seems that this vaccine is effective and using the same is not dangerous either.
This is the first step, taken in confirming procedure of the said vaccine. According to the said report, authorization for use of the said vaccines will be issued within the next three months accordingly.